ABPI chief exec backs Novartis legal challenge to off-label Avastin - PMLiVE
Avastin Injections Are Said to Cause Blindness - The New York Times
Roche - Avastin (bevacizumab)
Immunotherapy Regimen Approved for Hepatocellular Carcinoma - MPR
France wants Avastin used in place of Lucentis - PMLiVE
SecuringIndustry.com - More fake Avastin found, this time in Cyprus
Avastin Lawsuits - Off-Label Use, Eye Infection, Blindness Risk
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial - The Lancet Oncology
File:Bevacizumab label 01.jpg - wikidoc
Italy free to reimburse off-label Avastin, rules EU court -
PDF) Bevacizumab: Off-label use in ophthalmology
More Medicare Musings: Why Lucentis is Worth the Price Tag - Eyedolatry
Avastin - FDA prescribing information, side effects and uses
U.K. regulator supports off-label use of Avastin for serious eye condition
Avastin, Lucentis & Zaltrap, Eylea - ppt download
EFPIA Files Complaint Against French Law Promoting Off-Label Avastin Use – Policy & Medicine
Drug giants threaten NHS with legal action over cheaper drug that could save £84m a year | NHS | The Guardian
Avastin may fight early breast cancers in certain women | CTV News
FDA Says Avastin Not Safe or Effective for Patients With Breast Cancer
FDA Begins Process to Remove Breast Cancer Indication from Avastin Label - rgVision Magazine
Legal threat to NHS for using cheap drug Avastin | News | The Times
avastin - Diabetic Retinopathy
Doctors appeal to prescribe Avastin off-label | Pharmafile
Avastin now available in UK for ovarian cancer | Pharmafile
